Why You Keep Gaining Weight Back (NJ Insight)
Published by New Jersey Trim Clinic · Updated 2025-10-25
Weight Regain Isn't Your Fault
If you keep gaining weight back after losing it, you are in the same boat as the majority of dieters. Long-term studies show that 80–95% of people regain the weight they lose within 5 years.
This is not because you "let yourself go." It is because your body actively fights to return to its previous weight through a process called metabolic adaptation.
👉 Check If You Qualify in 2 Minutes
What Your Body Does After Weight Loss
After significant weight loss, your body:
- Burns 200–500 fewer calories per day than expected for your new weight
- Increases ghrelin (the hunger hormone)
- Decreases leptin (the satiety hormone)
- Reduces GLP-1 activity
This combination makes maintaining the loss almost impossible through lifestyle alone. Your biology is genuinely working against you.
Breaking the Regain Cycle
GLP-1 therapy interrupts this regain mechanism by sustaining satiety signaling and reducing hunger long-term. This is why GLP-1 medications are increasingly used as long-term maintenance — not just for weight loss, but to keep it off.
👉 Start Losing Weight This Week
NJ Trim Clinic Approach
Long-term physician oversight. $149/month all-inclusive. Telehealth across NJ, NY, CT, PA.
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.
Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Supports: Weight regain was observed after withdrawal of semaglutide and lifestyle intervention in the exploratory STEP 1 extension.
Evidence limits: The extension involved a subset of trial participants; it does not establish that every patient needs lifelong medication.
- NIH/NIDDK — Factors Affecting Weight & Health
Supports: Weight is influenced by lifestyle, sleep, medicines, health conditions, family history and other factors; insufficient sleep can affect hunger.
Evidence limits: This general guidance does not establish the cause of an individual patient's cravings, emotional eating, insulin resistance or weight changes.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
RESEARCH & REFERENCES
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. Diabetes, Obesity and Metabolism. 2021.
Research published in Diabetes, Obesity and Metabolism reported improvements in appetite and control of eating in a 20-week trial of semaglutide in adults with obesity.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Wilding JPH, Batterham RL, Davies M, et al.; STEP 1 Study Group. Diabetes, Obesity and Metabolism. 2022.
Research published in Diabetes, Obesity and Metabolism reported weight regain after treatment withdrawal in the STEP 1 extension.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.